Cited by 690Nicotinic Acetylcholine Receptors StudySchizophrenia research and treatmentNeuroscience and Neuropharmacology Research

The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.

Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia

Freedman, Robert, Hall, Michael, Adler, Lawrence E., Leonard, Sherry·1995·Biological Psychiatry

DOI 10.1016/0006-3223(94)00252-x

Open this paper in CoChat — free account

Abstract

This study tests the hypothesis that nicotinic cholinergic receptors, including those sensitive to the antagonist alpha-bungarotoxin, are decreased in the hippocampus of schizophrenics. The hypothesis is derived from the finding that alpha-bungarotoxin causes a defect in the inhibitory gating of auditory-evoked potentials in laboratory animals that resembles a defect in auditory sensory gating observed in schizophrenics. Nicotine transiently normalizes this psychophysiological deficit in schizophrenic patients. Postmortem brain tissue was obtained from eight schizophrenic and eight age-matched nonschizophrenic subjects. Sections of the hippocampus were labeled with [125I alpha-bungarotoxin and imagined by autoradiography. Binding of the nicotinic agonist [3H]-cytisine was determined in tissue homogenates. alpha-Bungarotoxin labeled a population of putative interneurons in the hippocampus, primarily in the dentate gyrus and the CA3 region of Ammon's horn. This labeling was significantly decreased in the tissue from the schizophrenic patients, with seven or eight patients below the range of the nonschizophrenic subjects. There was also a significant decrease in the binding of cytisine. The results were not related to generalized hippocampal cell loss, drug exposure at time of death, or smoking history. This initial study suggests that schizophrenic patients have fewer nicotinic receptors in the hippocampus, a condition which may lead to failure of cholinergic activation of inhibitory interneurons, manifest clinically as decreased gating of response to sensory stimulation.

Integrity signals

Registry

Crossref · 10.1016/0006-3223(94)00252-x

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
Progress in experimental personality research
Maher, W. B., & Maher, B. A. (1964) · Academic Press eBooks · Cited by 2,347
Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium
Séguéla, P., Wadiche, J. I., Dineley‐Miller, K., Dani, J., & Jw, P. (1993) · Journal of Neuroscience · doi:10.1523/jneurosci.13-02-00596.1993 · Cited by 1,471
Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia.
Adler, L. E., Pachtman, E., Franks, R. D., Pecevich, M., Waldo, M. C., & Freedman, R. (1982) · PubMed · Cited by 896
Self-citation
Deficits in Small Interneurons in Prefrontal and Cingulate Cortices of Schizophrenic and Schizoaffective Patients
Benes, F. M. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810350036005 · Cited by 891
Basal Ganglia and Limbic System Pathology in Schizophrenia: A Morphometric Study of Brain Volume and Shrinkage
Bogerts, B. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790310046006 · Cited by 880
A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment.
Flores, C. M., Rogers, S. W., Pabreza, L. A., Wolfe, B. B., & Kellar, K. J. (1992) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08832-7 · Cited by 880
Cigarette smoking: implications for psychiatric illness
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.4.546 · Cited by 723
Normalization of auditory physiology by cigarette smoking in schizophrenic patients
Adler, L. E., Hoffer, L., Wiser, A., & Freedman, R. (1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.12.1856 · Cited by 679
Self-citation
Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects
GOFF, D. C., Henderson, D. C., & Amico, E. (1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.9.1189 · Cited by 576

Show all 55 references

Research works printed but not linked: 3

Daviss, 1993, Calbindin- and calretinin-immunoreactive local circuit neurons are increased in density in the prefrontal cortex of schizophrenic subjects, Neurosci Abstracts, 19, 201
Goff, 1980, Neural origins of long latency evoked potentials recorded from the depth and from the cortical surface of the brain in man, Prog Clin Neurophysiol, 7, 126
Klein, 1991, On the influence of smoking upon smooth pursuit eye movements of schizophrenics and normal controls, J Psychophysiology, 5, 361

Sorted by citations

Items 201–300 of 690

Selective changes in the levels of nicotinic acetylcholine receptor protein and of corresponding mRNA species in the brains of patients with Parkinson’s disease
Guan, Z., Nordberg, A. K., Mousavi, M. T., Rinne, J. O., & Hellström‐Lindahl, E. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03571-0 · Cited by 68
Cholinesterase Inhibitors as Adjunctive Therapy in Patients with Schizophrenia and Schizoaffective Disorder
Ribeiz, S. R. I., Bassitt, D. P., Arrais, J., Ávila, R., Steffens, D. C., & Bottino, C. M. C. (2010) · CNS Drugs · doi:10.2165/11530260-000000000-00000 · Cited by 68
The Therapeutic Potential of α7 Nicotinic Acetylcholine Receptor (α7 nAChR) Agonists for the Treatment of the Cognitive Deficits Associated with Schizophrenia
Beinat, C., Banister, S. D., Herrera, M., Law, V., & Kassiou, M. (2015) · CNS Drugs · doi:10.1007/s40263-015-0260-0 · Cited by 68
Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial
Freudenreich, O., Herz, L. R., Deckersbach, T., Evins, A. E., Henderson, D. C., Cather, C., & GOFF, D. C. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2235-1 · Cited by 68
Cellular, molecular, and genetic substrates underlying the impact of nicotine on learning
Gould, T. J., & Leach, P. T. (2013) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.08.004 · Cited by 72
Targeting the Hippocampal Mossy Fiber Synapse for the Treatment of Psychiatric Disorders
Kobayashi, K. (2009) · Molecular Neurobiology · doi:10.1007/s12035-008-8049-5 · Cited by 70
Smoking, nicotine and psychiatric disorders: evidence for therapeutic role, controversies and implications for future research
Dursun, S. M., & Kutcher, S. (1999) · Medical Hypotheses · doi:10.1054/mehy.1997.0623 · Cited by 67
Old and New Pharmacology: Positive Allosteric Modulation of the α7 Nicotinic Acetylcholine Receptor by the 5-Hydroxytryptamine2B/C Receptor Antagonist SB-206553 (3,5-Dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b′]di pyrrole-1(2H)-carboxamide)
Dunlop, J., Lock, T., Jow, B., Sitzia, F., Grauer, S. M., Jow, F., Kramer, A., Bowlby, M., Randall, A. P., Kowal, D., et al. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.146514 · Cited by 71
Classics in Chemical Neuroscience: Xanomeline
Bender, A. M., Jones, C. K., & Lindsley, C. W. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00001 · Cited by 65
Tabac et schizophrénie : aspects épidémiologiques et cliniques
Dervaux, A., & Laqueille, X. (2008) · L Encéphale · doi:10.1016/j.encep.2007.04.003 · Cited by 66
Neurocognitive endophenotypes in schizophrenia: Modulation by nicotinic receptor systems
Mackowick, K. M., Barr, M. S., Wing, V. C., Rabin, R. A., Ouellet‐Plamondon, C., & George, T. P. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.07.010 · Cited by 65
Brain PET Imaging of α7-nAChR with [18F]ASEM: Reproducibility, Occupancy, Receptor Density, and Changes in Schizophrenia
Wong, D. F., Kuwabara, H., Horti, A. G., Roberts, J., Nandi, A., Cascella, N. G., Brašić, J. R., Weerts, E. M., Kitzmiller, K., Phan, J.-A., et al. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy021 · Cited by 66
Self-citation
Evidence for a role of nicotinic acetylcholine receptors in schizophrenia
Catherine, E. A. (2007) · Frontiers in bioscience · doi:10.2741/2424 · Cited by 63
Neuronal Nicotinic Receptor Subtypes: DEFINING THERAPEUTIC TARGETS
Buccafusco, J. J. (2004) · Molecular Interventions · doi:10.1124/mi.4.5.8 · Cited by 64
Cognitive Deficits in Schizophrenia: Focus on Neuronal Nicotinic Acetylcholine Receptors and Smoking
Ochoa, E. L. M., & Lasalde‐Dominicci, J. A. (2007) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-007-9149-x · Cited by 64
Nicotine and familial vulnerability to schizophrenia: A discordant twin study.
Lyons, M. J., Bar, J. L., Kremen, W. S., Toomey, R., Eisen, S. A., Goldberg, J. H., Faraone, S. V., & Tsuang, M. T. (2002) · Journal of Abnormal Psychology · doi:10.1037//0021-843x.111.4.687 · Cited by 62
α7 nicotinic acetylcholine receptor mRNA expression and binding in postmortem human brain are associated with genetic variation in neuregulin 1
Mathew, S., Law, A. J., Lipska, B. K., Dávila‐García, M. I., Zamora, E. D., Mitkus, S. N., Vakkalanka, R., Straub, R. E., Weinberger, D. R., Kleinman, J. E., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm253 · Cited by 63
Beauty of the beast: anticholinergic tropane alkaloids in therapeutics
Shim, K. H., Kang, M. J., Sharma, N., & An, S. S. A. (2022) · Natural Products and Bioprospecting · doi:10.1007/s13659-022-00357-w · Cited by 65
Presynaptic Type III Neuregulin1-ErbB signaling targets α7 nicotinic acetylcholine receptors to axons
Hancock, M., Canetta, S., Role, L. W., & Talmage, D. A. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200710037 · Cited by 62
Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the α7 nicotinic acetylcholine receptor: In vitro and in vivo activity
Acker, B. A., Jacobsen, E. J., Rogers, B. N., Wishka, D. G., Reitz, S. C., Piotrowski, D. W., Myers, J. K., Wolfe, M. L., Groppi, V. E., Thornburgh, B. A., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.04.070 · Cited by 61
Deletion of the α7 Nicotinic Receptor Subunit Gene Results in Increased Sensitivity to Several Behavioral Effects Produced by Alcohol
Bowers, B. J., McClure‐Begley, T. D., Keller, J. J., Paylor, R. E., Collins, A. C., & Wehner, J. M. (2005) · Alcoholism Clinical and Experimental Research · doi:10.1097/01.alc.0000156116.40817.a2 · Cited by 61
Neuronal Nicotinic Acetylcholine Receptors: Involvement in Alzheimer’s Disease and Schizophrenia
Woodruff‐Pak, D. S., & Gould, T. J. (2002) · Behavioral and Cognitive Neuroscience Reviews · doi:10.1177/1534582302001001002 · Cited by 60
Activation of α7 nicotinic receptors improves phencyclidine-induced deficits in cognitive tasks in rats: Implications for therapy of cognitive dysfunction in schizophrenia
McLean, S. L., Grayson, B., Idris, N. F., Lesage, A. S., Pemberton, D. J., Mackie, C. E., & Neill, J. C. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.06.003 · Cited by 60
Cortical parvalbumin GABAergic deficits with α7 nicotinic acetylcholine receptor deletion: implications for schizophrenia
Lin, H., Hsu, F., Baumann, B. H., Coulter, D. A., Anderson, S. A., & Lynch, D. R. (2014) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2014.06.007 · Cited by 60
Do Nicotinic Receptors Modulate High-Order Cognitive Processing?
Koukouli, F., & Changeux, J. (2020) · Trends in Neurosciences · doi:10.1016/j.tins.2020.06.001 · Cited by 63
[11C]CHIBA-1001 as a Novel PET Ligand for α7 Nicotinic Receptors in the Brain: A PET Study in Conscious Monkeys
Hashimoto, K., Nishiyama, S., Ohba, H., Matsuo, M., Kobashi, T., Takahagi, M., Iyo, M., Kitashoji, T., & Tsukada, H. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003231 · Cited by 59
Nicotinic Receptor Contributions to Smoking: Insights from Human Studies and Animal Models
Brunzell, D. H., Stafford, A. M., & Dixon, C. I. (2015) · Current Addiction Reports · doi:10.1007/s40429-015-0042-2 · Cited by 58
Modulation of alpha7 nicotinic receptor-mediated calcium influx by nicotinic agonists.
Quik, M., Philie, J., & Choremis, J. (1997) · PubMed · Cited by 59
Pro-Cognitive and Antipsychotic Efficacy of the α7 Nicotinic Partial Agonist SSR180711 in Pharmacological and Neurodevelopmental Latent Inhibition Models of Schizophrenia
Barak, S., Arad, M., Levie, A. D., Black, M. D., Griebel, G., & Weiner, I. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.232 · Cited by 57
Performance of α7 nicotinic receptor null mutants is impaired in appetitive learning measured in a signaled nose poke task
Keller, J. J., Keller, A. B., Bowers, B. J., & Wehner, J. M. (2005) · Behavioural Brain Research · doi:10.1016/j.bbr.2005.03.004 · Cited by 57
Effects of Nicotine on Hippocampal and Cingulate Activity During Smooth Pursuit Eye Movement in Schizophrenia
Tanabe, J., Tregellas, J. R., Martín, L., & Freedman, R. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.004 · Cited by 57
Self-citation
α7 nicotinic acetylcholine receptor activation ameliorates scopolamine-induced behavioural changes in a modified continuous Y-maze task in mice
Redrobe, J. P., Nielsen, E. Ø., Christensen, J. K., Peters, D., Timmermann, D. B., & Olsen, G. M. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.09.035 · Cited by 57
Assessment of Pharmacotherapy for Negative Symptoms of Schizophrenia
Hanson, E., Healey, K. M., Wolf, D. H., & Kohler, C. G. (2010) · Current Psychiatry Reports · doi:10.1007/s11920-010-0148-0 · Cited by 61
Chrna7 deficient mice manifest no consistent neuropsychiatric and behavioral phenotypes
Yin, J., Chen, W., Yang, H., Xue, M., & Schaaf, C. P. (2017) · Scientific Reports · doi:10.1038/srep39941 · Cited by 59
Beneficial Effect of Donepezil Augmentation for the Management of Comorbid Schizophrenia and Dementia
Stryjer, R., Strous, R. D., Bar, F., Werber, E. A., Shaked, G., Buhiri, Y., Kotler, M., Weizman, A., & Rabey, J. M. (2003) · Clinical Neuropharmacology · doi:10.1097/00002826-200301000-00004 · Cited by 57
The Developing Utility of Zebrafish Models for Cognitive Enhancers Research
Stewart, A., & Kalueff, A. V. (2012) · Current Neuropharmacology · doi:10.2174/157015912803217323 · Cited by 56
Visual hallucinations are associated with lower αbungarotoxin binding in dementia with Lewy bodies
COURT, J. A., Ballard, C. G., Piggott, M. A., Johnson, M., O'Brien, J. T., Holmes, C., Cairns, N. J., Lantos, P. L., Perry, R. H., Jaros, E., et al. (2001) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00644-x · Cited by 56
Loss of nicotinic acetylcholine receptor subunits α4 and α7 in the cerebral cortex of Parkinson patients
Burghaus, L., Schütz, U., Krempel, U., Lindstrom, J. M., & Schröder, H. (2003) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(03)00028-2 · Cited by 56
fMRI of Response to Nicotine During a Smooth Pursuit Eye Movement Task in Schizophrenia
Tregellas, J. R., Tanabe, J., Martín, L., & Freedman, R. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.2.391 · Cited by 55
Self-citation
Nicotine blocks apomorphine‐induced disruption of prepulse inhibition of the acoustic startle in rats: possible involvement of central nicotinic α7 receptors
Suemaru, K., Yasuda, K., Umeda, K., Araki, H., Shibata, K., Choshi, T., Hibino, S., & Gomita, Y. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705855 · Cited by 54
Cholinergic Agonists as Novel Treatments for Schizophrenia: The Promise of Rational Drug Development for Psychiatry
Lieberman, J. A., Javitch, J. A., & Moore, H. M. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08050769 · Cited by 53
Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker
Hashimoto, K. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150605111345 · Cited by 53
The nicotinic cholinergic system function in the human brain
Nees, F. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.10.021 · Cited by 57
Strain Dependent Effects of Prenatal Stress on Gene Expression in the Rat Hippocampus
Neeley, E. W., Berger, R., Koenig, J., & Leonard, S. (2011) · Physiology and Behavior · doi:10.1016/j.physbeh.2011.02.032 · Cited by 52
Self-citation
Regulation of α7‐nicotinic receptor subunit and α7‐like gene expression in the prefrontal cortex of patients with bipolar disorder and schizophrenia
Luca, V. D., Likhodi, O., Tol, H. H. M. V., Kennedy, J. L., & Wong, A. H. C. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00785.x · Cited by 52
Reversal of isolation-rearing-induced PPI deficits by an α7 nicotinic receptor agonist
Cilia, J., Cluderay, J. E., Robbins, M. J., Reavill, C., Southam, E., Kew, J. N. C., & Jones, D. N. C. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0069-5 · Cited by 53
A Novel Permutation Testing Method Implicates Sixteen Nicotinic Acetylcholine Receptor Genes as Risk Factors for Smoking in Schizophrenia Families
Faraone, S. V., Lasky-Su, J. A., Taylor, L., Wilcox, M., Eerdewegh, P. V., & Tsuang, M. T. (2004) · Human Heredity · doi:10.1159/000077543 · Cited by 53
The Impact of Neurotransmitters on the Neurobiology of Neurodegenerative Diseases
Davis, S. E., Cirincione, A. B., Jiménez-Torres, A. C., & Zhu, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015340 · Cited by 55
[3H]A-585539 [(1 S,4 S)-2,2-Dimethyl-5-(6-phenylpyridazin-3-yl)-5-aza-2-azoniabicyclo[2.2.1]heptane], a Novel High-Affinity α7 Neuronal Nicotinic Receptor Agonist: Radioligand Binding Characterization to Rat and Human Brain
Anderson, D. J., Bunnelle, W. H., Surber, B. W., Du, J. Y., Surowy, C. S., Tribollet, E., Marguerat, A., Bertrand, D., & Gopalakrishnan, M. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.130062 · Cited by 52
Familial transmission of risk factors in the first-degree relatives of schizophrenic people
Waldo, M. C., Adler, L. E., Leonard, S. S., D, A. O. M., Ross, R. G., Harris, J. G., & Freedman, R. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00272-3 · Cited by 52
Self-citation
Schizophrenia: A unique translational opportunity in behavioral neuroendocrinology
Koenig, J. I. (2006) · Hormones and Behavior · doi:10.1016/j.yhbeh.2006.06.027 · Cited by 51
Novel α7 nicotinic receptor isoforms and deficient cholinergic transcription in schizophrenia
Severance, E. G., & Yolken, R. H. (2007) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2007.00323.x · Cited by 51
Discovery of (2S,3R)-N-[2-(Pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]benzo[b]furan-2-carboxamide (TC-5619), a Selective α7 Nicotinic Acetylcholine Receptor Agonist, for the Treatment of Cognitive Disorders
Mazurov, A. A., Kombo, D. C., Hauser, T. A., Miao, L., Dull, G. M., Genus, J. F., Fedorov, N. B., Benson, L., Sidach, S. S., Xiao, Y.-D., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301048a · Cited by 51
Rivastigmine treatment as an add‑on to antipsychotics in patients with schizophrenia and cognitive deficits
Chouinard, S., Stip, É., Poulin, J., Melun, J.-P., Godbout, R., Guillem, F., & Cohen, H. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x167372 · Cited by 51
Physiologic Functions and Therapeutic Applications of α7 Nicotinic Acetylcholine Receptor in Brain Disorders
Lee, C.-H., & Hung, S.-Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010031 · Cited by 50
The Molecular and Cellular Neurobiology of Nicotine Abuse in Schizophrenia
Mobascher, A., & Winterer, G. (2008) · Pharmacopsychiatry · doi:10.1055/s-2008-1081463 · Cited by 50
Varenicline Treatment for Smokers With Schizophrenia
Evins, A. E., & GOFF, D. C. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0620a · Cited by 49
Recent advances in treating cognitive impairment in schizophrenia
Galletly, C. A. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1302-9 · Cited by 49
Efficacy and Tolerability of Low-Dose Donepezil in Schizophrenia
Erickson, S. K., Schwarzkopf, S. B., Palumbo, D. R., Badgley-Fleeman, J., Smirnow, A. M., & Light, G. A. (2005) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000173714.61744.e6 · Cited by 50
The molecular genetics of schizophrenia: an emerging consensus
Faraone, S. V., Taylor, L., & Tsuang, M. T. (2002) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399402004751 · Cited by 50
REVIEW: Cognitive effects of nicotine: genetic moderators
Herman, A. I., & Sofuoglu, M. (2010) · Addiction Biology · doi:10.1111/j.1369-1600.2010.00213.x · Cited by 52
A 3-year retrospective cohort study of predictors of relapse in first-episode psychosis in Hong Kong
Hui, C. L. M., Tang, J. Y. ‐., Leung, C., Wong, G. H. Y., Chang, W. C., Chan, S. K. W., Lee, E. H. M., & Chen, E. Y. H. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867413487229 · Cited by 49
α4β2 Nicotinic receptor stimulation contributes to the effects of nicotine in the DBA/2 mouse model of sensory gating
Radek, R. J., Miner, H. M., Bratcher, N. A., Decker, M. W., Gopalakrishnan, M., & Bitner, R. S. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0394-3 · Cited by 49
Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy
Ferreri, F., Agbokou, C., & Gauthier, S. G. (2006) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0641 · Cited by 49
Chronic exposure to typical or atypical antipsychotics in rodents: Temporal effects on central α7 nicotinic acetylcholine receptors
Terry, A. V., Gearhart, D. A., Mahadik, S. P., Warsi, S., Davis, L. W., & Waller, J. L. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.08.006 · Cited by 49
Predictors of Early Abstinence in Smokers With Schizophrenia
Maravić, M. C., Schoenfeld, D., Barr, R. S., Cather, C., Deckersbach, T., Freudenreich, O., GOFF, D. C., Rigotti, N. A., & Evins, A. E. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n1109 · Cited by 48
Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of tropisetron: role of alpha7 nicotinic receptors.
Hashimoto, K., Fujita, Y., Ishima, T., Hagiwara, H., & Iyo, M. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.09.055 · Cited by 59
Neuronal Nicotinic Receptor and Psychiatric Disorders: Functional and Behavioral Effects of Nicotine
Araki, H., Suemaru, K., & Gomita, Y. (2002) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.88.133 · Cited by 48
Neuroinflammation Modulation via α7 Nicotinic Acetylcholine Receptor and Its Chaperone, RIC-3
Mizrachi, T., Vaknin‐Dembinsky, A., Brenner, T., & Treinin, M. (2021) · Molecules · doi:10.3390/molecules26206139 · Cited by 46
Hippocampal α7 nicotinic acetylcholine receptor levels in patients with schizophrenia, bipolar disorder, or major depressive disorder
Thomsen, M. S., Weyn, A., & Mikkelsen, J. D. (2011) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00961.x · Cited by 47
Modeling cholinergic aspects of schizophrenia: Focus on the antimuscarinic syndrome
Barak, S. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.04.006 · Cited by 50
Nicotine Effects on Mismatch Negativity in Nonsmoking Schizophrenic Patients
Inami, R., Kirino, E., Inoue, R., Suzuki, T., & Arai, H. (2007) · Neuropsychobiology · doi:10.1159/000111536 · Cited by 45
Psychopharmacological treatment of schizophrenia: What do we have, and what could we get?
Ellenbroek, B. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.03.013 · Cited by 46
A Type-II Positive Allosteric Modulator of α7 nAChRs Reduces Brain Injury and Improves Neurological Function after Focal Cerebral Ischemia in Rats
Sun, F., Jin, K., & Uteshev, V. V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073581 · Cited by 47
Homomeric and Heteromeric α7 Nicotinic Acetylcholine Receptors in Health and Some Central Nervous System Diseases
Borroni, V., & Barrantes, F. J. (2021) · Membranes · doi:10.3390/membranes11090664 · Cited by 49
Chronic treatment with first or second generation antipsychotics in rodents: Effects on high affinity nicotinic and muscarinic acetylcholine receptors in the brain
Terry, A. V., Gearhart, D. A., Mahadik, S. P., Warsi, S., & Waller, J. L. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.03.011 · Cited by 46
Nicotinic receptor losses in dementia with Lewy bodies: comparisons with Alzheimer's disease.
Reid, R., Sabbagh, M., Bloom, J. C., Tiraboschi, P., & Thal, L. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00168-8 · Cited by 45
α7-Nicotinic receptor expression and the anatomical organization of hippocampal interneurons
Adams, C. E., Stitzel, J. A., Collins, A. C., & Freedman, R. (2001) · Brain Research · doi:10.1016/s0006-8993(01)03115-8 · Cited by 45
Self-citation
Antiretroviral antibodies: implications for schizophrenia, schizophrenia spectrum disorders, and bipolar disorder
Hart, D. J., Heath, R. G., Sautter, F. J., Schwartz, B. D., Garry, R. F., Choi, B., Beilke, M. A., & Hart, L. K. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00229-7 · Cited by 45
In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia
Redrobe, J. P., Jørgensen, M., Christoffersen, C. T., Montezinho, L. P., Bastlund, J. F., Carnerup, M. A., Bundgaard, C., Lerdrup, L., & Plath, N. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3492-7 · Cited by 44
Nicotine increases brain functional network efficiency
Wylie, K. P., Rojas, D. C., Tanabe, J., Martín, L., & Tregellas, J. R. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.06.079 · Cited by 43
Early nicotine withdrawal and transdermal nicotine effects on neurocognitive performance in schizophrenia
AhnAllen, C. G., Nestor, P. G., Shenton, M. E., McCarley, R. W., & Niznikiewicz, M. A. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.07.030 · Cited by 44
Nicotinic receptors as targets for therapeutic discovery
Lippiello, P., Bencherif, M., Hauser, T. A., Jordan, K., Letchworth, S., & Mazurov, A. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.9.1185 · Cited by 43
Differential effects of nicotine on P50 amplitude, its gating, and their neural sources in low and high suppressors
Knott, V., Fisher, D. J., & Millar, A. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.07.012 · Cited by 44
Functional alterations of nicotinic neurotransmission in dopamine transporter knock-out mice
Weiss, S., Tzavara, E. T., Davis, R. J., Nomikos, G. G., McIntosh, J. M., Giros, B., & Martres, M. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.02.002 · Cited by 44
Distribution of mRNA for the α4 subunit of the nicotinic acetylcholine receptor in the human fetal brain
Agulhon, C., Charnay, Y., Vallet, P. G., Bertrand, D., & Malafosse, A. (1998) · Molecular Brain Research · doi:10.1016/s0169-328x(98)00113-2 · Cited by 43
(R)-3‘-(3-Methylbenzo[b]thiophen-5-yl)spiro[1-azabicyclo[2,2,2]octane-3,5‘-oxazolidin]-2‘-one, a Novel and Potent α7 Nicotinic Acetylcholine Receptor Partial Agonist Displays Cognitive Enhancing Properties
Tatsumi, R., Fujio, M., Takanashi, S.-I., Numata, A., Katayama, J., Satoh, H., Shiigi, Y., Maeda, J.-I., Kuriyama, M., Horikawa, T., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060249c · Cited by 42
A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia
Lee, B. J., Lee, J.-G., & Kim, Y.-H. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106070996 · Cited by 42
Diverse strategies targeting α7 homomeric and α6β2* heteromeric nicotinic acetylcholine receptors for smoking cessation
Brunzell, D. H., McIntosh, J. M., & Papke, R. L. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12421 · Cited by 43
Cotinine halts the advance of Alzheimer's disease-like pathology and associated depressive-like behavior in Tg6799 mice
Patel, S. P., Grizzell, J. A., Holmes, R., Zeitlin, R., Solomon, R., Sutton, T. L., Rohani, A., Charry, L. C., Iarkov, A., Mori, T., et al. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00162 · Cited by 41
Pharmacokinetic Limitations on Effects of an Alpha7-Nicotinic Receptor Agonist in Schizophrenia: Randomized Trial with an Extended-Release Formulation
Kem, W. R., D, A. O. M., Johnson, L. L., Harris, J., Wagner, B. D., Buchanan, R. W., Christians, U., & Freedman, R. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.182 · Cited by 40
Self-citation
P50 inhibitory sensory gating in schizophrenia: analysis of recent studies
Freedman, R., Olsen-Dufour, A. M., & D, A. O. M. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.02.003 · Cited by 45
Self-citation
Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders
Terry, A. V., Callahan, P. M., & Hernandez, C. M. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.07.027 · Cited by 40
Spatial and intracellular relationships between the α7 nicotinic acetylcholine receptor and the vesicular acetylcholine transporter in the prefrontal cortex of rat and mouse
Duffy, Á. M., Zhou, P., Milner, T. A., & Pickel, V. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.04.024 · Cited by 49
Alpha‐7 nicotinic acetylcholine receptor agonists selectively activate limbic regions of the rat forebrain: An effect similar to antipsychotics
Hansen, H. H., Timmermann, D. B., Peters, D., Walters, C. L., Damaj, M. I., & Mikkelsen, J. D. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21293 · Cited by 40
Nicotinic acetylcholine receptor ligands, a patent review (2006 – 2011)
Gündisch, D., & Eibl, C. (2011) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.637919 · Cited by 39
Chronic corticosterone treatment alters sensory gating in C3H mice
Stevens, K. E., Bullock, A. E., & Collins, A. C. (2001) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00523-8 · Cited by 40
Neurotoxins Acting at Synaptic Sites: A Brief Review on Mechanisms and Clinical Applications
Zhou, K., Luo, W., Liu, T., Ni, Y., & Qin, Z. (2022) · Toxins · doi:10.3390/toxins15010018 · Cited by 43
Schizophrenia and Substance Abuse Comorbidity: Nicotine Addiction and the Neonatal Quinpirole Model
Brown, R. W., Maple, A. M., Perna, M. K., Sheppard, A. B., Cope, Z. A., & Kostrzewa, R. M. (2012) · Developmental Neuroscience · doi:10.1159/000338830 · Cited by 39
Drug Discovery on Natural Products: From Ion Channels to nAChRs, from Nature to Libraries, from Analytics to Assays
Otvos, R. A., Still, K. B. M., Somsen, G. W., Smit, A. B., & Kool, J. (2019) · SLAS DISCOVERY · doi:10.1177/2472555218822098 · Cited by 43

Authors: Freedman, R., Hall, M., Adler, L. E., & Leonard, S.
Affiliations: Denver VA Medical Center (US)
University of Colorado Denver (US)
Corresponding author: Freedman, Robert
ORCID: Freedman, Robert
Hall, Michael
Venue: Biological Psychiatry
Publisher: Elsevier BV
Published: 1995-07
Volume: 38
Issue: 1
Pages: 22-33
ISSN: 0006-3223 (ISSN-L)
DOI: 10.1016/0006-3223(94)00252-x
OpenAlex: W2090019512
Cited by: 678
References: 55
Citations by year: 2026: 2 · 2025: 10 · 2024: 8 · 2023: 12 · 2022: 11 · 2021: 16 · 2020: 18 · 2019: 17 · 2018: 11 · 2017: 17 · 2016: 18 · 2015: 34 · 2014: 29 · 2013: 27 · 2012: 30
FWCI: 3.72
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Biological Psychiatry (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (1k01mh000728-01a1)
National Institute of Mental Health (MH-44212, MH00728, MH 38321, P50MH044212)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords: schizophrenia, nicotinic acetylcholine receptors, hippocampus, alpha-bungarotoxin binding, auditory gating, inhibitory interneurons, dentate gyrus, CA3 region, postmortem brain, cholinergic dysfunction
MeSH terms: Quinolizidine Alkaloids, Adult, Aged, Alkaloids, Autoradiography, Azocines, Binding Sites, Bungarotoxins, Cell Count, Female, Hippocampus, Humans, Image Processing, Computer-Assisted, Male, Middle Aged, Quinolizines, Receptors, Nicotinic, Schizophrenia, Cholinergic Agents, Dentate Gyrus, Culture Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks